Sparrow Pharma Unveils Phase 2 Data on Clofutriben for PMR

Sparrow Pharma Unveils Phase 2 Data on Clofutriben for PMR

By Daniella Parra Sparrow Pharmaceuticals shared data on the combination of clofutriben (SPI-62), an HSD-1 inhibitor, and prednisolone for treating polymyalgia rheumatica (PMR). The company said that HSD-1 inhibition can reduce glucocorticoid side effects while maintaining treatment efficacy and combining...

Nanox Integrates AI for Enhanced Second Opinion CT Scan Reviews

Nanox Integrates AI for Enhanced Second Opinion CT Scan Reviews

By Daniella Parra NANO-X IMAGING LTD (Nasdaq: NNOX) has integrated FDA-cleared AI solutions into its Second Opinions online consultation service, offered by its subsidiary, USARAD Holdings INC, the company said. This platform connects patients with specialists for additional diagnostic consultations,...

Aktis Oncology Appoints Ken Herrmann to Board of Directors

Aktis Oncology Appoints Ken Herrmann to Board of Directors

By Karen Roman Aktis Oncology said it appointed Dr. Ken Herrmann to the Board of Directors. Dr. Herrmann specializes in nuclear medicine and has over a decade of experience in clinical investigation, the company said. “Ken’s joining us on the...

The Duckhorn Portfolio Confirms Guidance for 2024

The Duckhorn Portfolio Confirms Guidance for 2024

By Karen Roman The Duckhorn Portfolio, Inc. (NYSE: NAPA) reported net sales increased 1.4% year over year to reach $92.5 million in its Q3 2024 results. Adjusted EBITDA grew 5.3% to $37.7 million year over year and adjusted EBITDA margin...

MOBILion Shows Off MOBIE System at ASMS 2024

MOBILion Shows Off MOBIE System at ASMS 2024

By Karen Roman MOBILion Systems announced it is presenting the latest features of its mass spectrometry platform, MOBIE EyeOn 2.3, at the 72nd American Society for Mass Spectrometry (ASMS) Conference in California. The latest software introduces new capabilities and streamlines...

Sparrow Pharmaceuticals Announces Cushing’s Syndrome Treatment Results

Sparrow Pharmaceuticals Announces Cushing’s Syndrome Treatment Results

By Daniella Parra Sparrow Pharmaceuticals said its HSD-1 inhibitor, clofutriben (SPI-62), normalized urine free cortisol in over 60% of patients with endogenous Cushing’s syndrome without significantly lowering serum cortisol, minimizing the risk of adrenal insufficiency. Traditional EnCS treatments require careful...

Input your search keywords and press Enter.